NDA 212937 · Fennec Pharms INC
Pedmark
Sodium Thiosulfate · Intravenous
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Sep 20, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Sep 20, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
65
12 Phase 3, 15 recruiting
FAERS reports
560
467 serious, 81 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 27, 2025.
PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. Limitations of Use The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred. PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. ( 1 ) Limitations of Use: The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.
Mechanism: Cisplatin-induced ototoxicity is caused by irreversible damage to hair cells in the cochlea hypothesized to be due to a combination of reactive oxygen species (ROS) production and direct alkylation of DNA leading to cell death. Sodium thiosulfate interacts directly with cisplatin to produce an inactive platinum species. In addition, sodium thiosulfate can enter cells through the sodium sulfate cotransporter 2 and cause intracellular effects such as the increase in antioxidant glutathione levels and inhibition of intracellular oxidative stress. Both activities may contribute to the ability of...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 20, 2022 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanLabelLetterReview
1 products under this application
- PEDMARK · SODIUM THIOSULFATE 12.5GM/100ML (125MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Thiosulfate" as an intervention, any sponsor and status, largest first.
- Sodium Thiosulfate to Preserve Cardiac Function in STEMIPivotal-lookingStatus unknown
University Medical Center GroningenAcademic, hospital or other
NCT02899364 · 380 participants (planned) · Start Jul 20, 2018 · Primary completion Jun 25, 2021
Drug: Sodium thiosulfate; Sodium chloride 0.9% · For: Myocardial Infarction; Heart Failure
Sites: Emmen, Netherlands; Groningen, Netherlands; Utrecht, Netherlands
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)Pivotal-lookingActive, not recruiting
Centre Oscar LambretAcademic, hospital or other
NCT03842982 · 362 participants (planned) · Start May 3, 2019 · Primary completion Feb 1, 2031
Drug: HIPEC · For: Ovary Neoplasms; Ovarian Cancer; Ovarian Carcinoma
Sites: Brussels, Belgium; Angers, France; Bordeaux, France · 18 sites in all
- Better Evidence and Translation for CalciphylaxisPivotal-lookingRecruiting
University of SydneyAcademic, hospital or other
NCT05018221 · 350 participants (planned) · Start Aug 26, 2021 · Primary completion Dec 2029
Drug: Vitamin K1; Magnesium citrate and 4 more · For: Calciphylaxis
Sites: Concord, Australia; Kogarah, Australia; Liverpool, Australia · 21 sites in all
- A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT StrategyPivotal-lookingRecruiting
Shanghai Children's Medical CenterAcademic, hospital or other
NCT04478292 · 330 participants (planned) · Start Mar 1, 2021 · Primary completion Mar 31, 2027
Drug: Sodium Thiosulfate Injection; mono CDDP-Group A2 and 5 more · For: Hepatoblastoma
Sites: Shanghai, China
- Clinical Evaluation of T.R.U.E. TEST® : Safety and EfficacyPivotal-lookingCompleted
AllerdermIndustry
NCT00640614 · 235 participants · Start Apr 2008 · Primary completion Aug 2009
Drug: T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens · For: Contact Dermatitis
Sites: Little Rock, Arkansas; Shawnee Mission, Kansas; Louisville, Kentucky · 5 sites in all
- A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing LossPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT05382338 · 225 participants (planned) · Start Feb 20, 2023 · Primary completion Dec 31, 2029
Drug: Cisplatin; Cyclophosphamide and 3 more · For: Childhood Medulloblastoma
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 111 sites in all
Brigham and Women's HospitalAcademic, hospital or other
NCT00571298 · 141 participants · Start Nov 2007 · Primary completion Nov 2011
Drug: Cisplatin; gemcitabine and 2 more · For: Malignant Pleural Mesothelioma
Sites: Boston, Massachusetts
- The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol ChromoendoscopyPivotal-lookingCompleted
Xijing Hospital of Digestive DiseasesAcademic, hospital or other
NCT04764643 · 140 participants · Start Feb 1, 2020 · Primary completion Apr 30, 2021
Drug: N-acetylcysteine solution; sodium thiosulfate solution · For: Esophageal Squamous Cell Carcinoma
Sites: Xi'an, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use154
- calciphylaxis89
- nausea88
- drug ineffective57
- vomiting54
- metabolic acidosis31
- sepsis23
- condition aggravated21
- pruritus21
- fatigue20
- death19
- headache19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 4 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 7 |
| 2011 | 19 |
| 2012 | 3 |
| 2013 | 11 |
| 2014 | 12 |
| 2015 | 14 |
| 2016 | 15 |
| 2017 | 32 |
| 2018 | 23 |
| 2019 | 29 |
| 2020 | 38 |
| 2021 | 45 |
| 2022 | 43 |
| 2023 | 41 |
| 2024 | 79 |
| 2025 | 68 |
| 2026 | 63 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
Brock PR, Maibach R, Childs M, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature.
Traineau H, Aggarwal R, Monfort JB, et al. · J Am Acad Dermatol 2020 · Systematic Review
- Interventions To Attenuate Vascular Calcification Progression in Chronic Kidney Disease: A Systematic Review of Clinical Trials.
Xu C, Smith ER, Tiong MK, et al. · J Am Soc Nephrol 2022 · Systematic Review
- Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
Freyer DR, Chen L, Krailo MD, et al. · Lancet Oncol 2017 · Clinical Trial, Phase III, Comparative Study
- Sodium azide poisoning: a narrative review.
Tat J, Heskett K, Satomi S, et al. · Clin Toxicol (Phila) 2021 · Systematic Review
- The Effect of Sodium Thiosulfate on Coronary Artery Calcification in Hemodialysis Patients.
Bian Z, Zhang Q, Shen L, et al. · ASAIO J 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Fennec Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.